Cohance Lifesciences Limited has informed the Exchange about Investor Presentation

Cohance Lifesciences (formerly Suven Pharmaceuticals) reported FY26 revenue of INR 22.7 billion, down 13% YoY, impacted by de-stocking in two large commercial products and regulatory disruptions. Adjusted EBITDA stood at INR 4.8 billion with 21% margins, while adjusted PAT was INR 1.8 billion at 8.1% margins. Q4FY26 revenue declined 26% YoY to INR 6.2 billion with adjusted EBITDA at INR 1.3 billion (21% margins). Gross margins improved 209 bps to 70.8% supported by product mix and subsidiary consolidation. The company ended FY26 with net cash of INR 1.5 billion and generated free cash flow of INR 1.73 billion. Management guided that FY27 will be a growth year weighted towards 2H, with Q1 expected to be the low point due to shipment phasing and higher operating costs. Pipeline remains robust with 10 Phase III molecules and 2x RFP inflows in small molecules.